Suppr超能文献

体外淋巴细胞刺激的细胞数量要求:多发性硬化病程中的变化及免疫抑制的影响

Cell number requirements for lymphocyte stimulation in vitro: changes during the course of multiple sclerosis and the effects of immunosuppression.

作者信息

Knight S C, Harding B, Burman S, Mertin J

出版信息

Clin Exp Immunol. 1981 Oct;46(1):61-9.

Abstract

Peripheral blood lymphocytes from 20 patients with clinically definite, relapsing and remitting multiple sclerosis (MS) were studied during their participation in a double-blind trial of immunosuppressive treatment. Proliferative responses occurring with different numbers of cells in culture and on different days of culture in the presence of phytohaemagglutinin (PHA) or with allogeneic cells from lymphoid cell lines (MLC) were assessed. Cells taken from patients before treatment showed similar responses to cells from laboratory personnel. However, when cells were taken from patients in relapse or from untreated patients as the disease progressed, there was an alteration in the pattern of response; higher number of cells were required in culture to produce responses. A change in the responsiveness to PHA or in MLC may therefore accompany the progression of the disease in MS (reflecting clinical relapses and possibly subclinical activity of the disease), perhaps resulting from a simple reduction in the proportion of cells able to respond. After intense immunosuppression followed by long-term maintenance on azathioprine, cells from patients gave similar responses to those found before treatment. Thus long-term immunosuppression prevented the progressive alteration in lymphocyte function. Shifts in the total cell number and time in culture required to allow proliferation with mitogens of cells from untreated MS patients could explain both the 'low' of PHA responses reported and the changes of in vitro 'suppressor' function of these cells.

摘要

在20例临床确诊的复发缓解型多发性硬化症(MS)患者参与免疫抑制治疗双盲试验期间,对其外周血淋巴细胞进行了研究。评估了在存在植物血凝素(PHA)的情况下,不同培养细胞数量以及培养不同天数时的增殖反应,以及与来自淋巴细胞系的同种异体细胞(MLC)共同培养时的增殖反应。治疗前取自患者的细胞与取自实验室人员的细胞表现出相似的反应。然而,当从复发期患者或疾病进展过程中未治疗患者身上采集细胞时,反应模式发生了改变;培养中需要更多数量的细胞才能产生反应。因此,MS疾病进展过程中可能会伴随对PHA或MLC反应性的变化(反映临床复发以及可能的疾病亚临床活动),这可能是由于能够做出反应的细胞比例简单降低所致。在进行强烈免疫抑制并随后长期使用硫唑嘌呤维持治疗后,患者的细胞产生的反应与治疗前相似。因此,长期免疫抑制可防止淋巴细胞功能的渐进性改变。未经治疗的MS患者细胞与有丝分裂原一起增殖所需的总细胞数和培养时间的变化,可以解释所报道的PHA反应“低下”以及这些细胞体外“抑制”功能的变化。

相似文献

引用本文的文献

本文引用的文献

8
Transfer factor in treatment of multiple sclerosis.转移因子在多发性硬化症治疗中的应用
Lancet. 1980 Nov 1;2(8201):931-4. doi: 10.1016/s0140-6736(80)92100-5.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验